Protein Information

ID 983
Name parathyroid hormone
Synonyms PTH; Parathormone; Parathyrin; Parathyroid hormone; Parathyroid hormone precursor; Parathormones; Parathyrins; Parathyroid hormones…

Compound Information

ID 1794
Name ergocalciferol
CAS

Reference

PubMed Abstract RScore(About this table)
19553166 Maheut H, Chevriot F, Marty H, Lavaud S, Kazes I, Chanard J, Rieu P: [Why and how correct calcidiol deficiency in haemodialysis patients?] . Nephrol Ther. 2009 Nov;5(6):542-9. Epub 2009 Jun 23.
The plasma concentration of 25 (OH) D - calcidiol - is low in most of stage 5 renal patients. Due to the lack of renal 1alpha-hydroxylase, no supplementation is recommended. However, calcidiol also displays many extraosseous beneficial antiproliferative effects. It may be useful to correct its deficiency in dialysis patients. The efficacy of an oral supplementation for 6 months with ergocalciferol, (Sterogyl), was evaluated in a monocentric cohort of 107 prevalent hemodialysis patients. Plasma levels of 25 (OH) D, parathormone, total and ionized calcium, phosphates, were measured at month 0, 3 and 6 in all patients and plasma levels of 1-25 (OH) D at month 0 and 6 in 38 patients with the lowest 25 (OH) D levels at baseline. Patients were divided into four groups according to their initial 25 (OH) D plasma levels and received ergocalciferol supplementation in accordance to the KDOQI Guidelines for stage 3 and 4 renal patients. RESULTS: 101/107 patients display low levels of 25 (OH) D at baseline: mean 11.8+/-11.6 microg/l (normal> 30 microg/l). At the end of the initial three months correction period, the plasma levels of 25 (OH) D rose significantly. However, only 60% of patients reach a normal plasma concentration of calcidiol with the highest - 600,000UI - ergocalciferol cumulative dosage. At the end of the three months maintenance period, plasma 25 (OH) D concentrations fell in all patients. No significant change was observed in parathormone, calcium, phosphates and 1-25 (OH) D plasma levels. There was no hypercalcemic episode. CONCLUSION: KDOQI ergocalciferol recommended doses for stages 3 and 4 renal patients did not correct calcidiol deficiency in hemodialysis patients. New prospective studies are required for defining the modalities of an efficient vitamin D supplementation with ergocalciferol or cholecalciferol.
1(0,0,0,1)